FDASRA Act of 2022
Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and… Show full official titleShow less
Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022
This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 4535: FDASRA Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-S-4535/
"S. 4535: FDASRA Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-4535/.
S. 4535, 117th Cong. (2026), https://openamerica.io/bill/117-S-4535/.
[S. 4535: FDASRA Act of 2022](https://openamerica.io/bill/117-S-4535/)